Table 3 Visiting schedule and procedures for TB participants (Cases)
Study day | Screening and enrolment | Visit 1 | Contact 1 |
|---|---|---|---|
Day 0 | Day 1–5 (no treatment) (Bronchoscopy) | 72 h and day 14 post bronchoscopy call | |
Informed consent including bronchoscopy consent and genetic testing consent | x | ||
Inclusion/exclusion criteria | x | ||
Targeted physical examination | x | x | |
Vital signs and medical history | x | x | |
Concomitant medications | x | ||
Chest X-ray | x | ||
ECG (If clinically indicated) | x | ||
Finger prick blood (Hb, random glucose, HbA1c, if indicated) | x | ||
HIV-1 rapid counselling and test | x | ||
Sputum (for GeneXpert®, smear & MGIT) | x | ||
PAXgene® | x | ||
Urine βHCG (all females) | x | ||
NaHep (PBMC) | x | x | |
Bronchoscopy (BAL) | xa | ||
Serum | x (SARS-CoV-2 serology) | x | |
Nasopharyngeal swab (for SARS-CoV-2 PCR & respiratory pathogen assays) | x | ||
Phone call and symptom check | x |